Annual FCF
-$12.88 M
+$9.47 M+42.37%
December 31, 2023
Summary
- As of February 7, 2025, ENTO annual free cash flow is -$12.88 million, with the most recent change of +$9.47 million (+42.37%) on December 31, 2023.
- During the last 3 years, ENTO annual FCF has fallen by -$1.65 million (-14.72%).
- ENTO annual FCF is now -207.01% below its all-time high of -$4.19 million, reached on December 1, 2015.
Performance
ENTO Free Cash Flow Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly FCF
-$1.85 M
+$1.60 M+46.43%
September 1, 2024
Summary
- As of February 7, 2025, ENTO quarterly free cash flow is -$1.85 million, with the most recent change of +$1.60 million (+46.43%) on September 1, 2024.
- Over the past year, ENTO quarterly FCF has increased by +$1.59 million (+46.26%).
- ENTO quarterly FCF is now -189.96% below its all-time high of -$637.50 thousand, reached on March 1, 2016.
Performance
ENTO Quarterly FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM FCF
-$12.49 M
+$1.48 M+10.61%
September 1, 2024
Summary
- As of February 7, 2025, ENTO TTM free cash flow is -$12.49 million, with the most recent change of +$1.48 million (+10.61%) on September 1, 2024.
- Over the past year, ENTO TTM FCF has dropped by -$107.90 thousand (-0.87%).
- ENTO TTM FCF is now -1104.15% below its all-time high of -$1.04 million, reached on March 1, 2015.
Performance
ENTO TTM FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Free Cash Flow Formula
FCF = Cash From Operations − CAPEX
ENTO Free Cash Flow Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +42.4% | +46.3% | -0.9% |
| 3 y3 years | -14.7% | +35.0% | +27.7% |
| 5 y5 years | -17.9% | +55.5% | +1.8% |
ENTO Free Cash Flow Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +69.8% | at high | +88.5% | -0.9% | +72.5% |
| 5 y | 5-year | -14.7% | +69.8% | -42.7% | +88.5% | -45.7% | +72.5% |
| alltime | all time | -207.0% | +69.8% | -190.0% | +88.5% | -1104.2% | +72.5% |
Entero Therapeutics Free Cash Flow History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$1.85 M(-46.4%) | -$12.49 M(-10.6%) |
| Jun 2024 | - | -$3.45 M(-7.9%) | -$13.97 M(+5.2%) |
| Mar 2024 | - | -$3.75 M(+8.9%) | -$13.28 M(+7.3%) |
| Dec 2023 | -$12.88 M(-42.4%) | -$3.44 M(+3.2%) | -$12.38 M(-14.8%) |
| Sep 2023 | - | -$3.33 M(+20.6%) | -$14.53 M(-6.0%) |
| Jun 2023 | - | -$2.76 M(-2.9%) | -$15.45 M(-10.6%) |
| Mar 2023 | - | -$2.85 M(-49.1%) | -$17.28 M(-22.7%) |
| Dec 2022 | -$22.34 M(-47.6%) | - | - |
| Dec 2022 | - | -$5.59 M(+31.5%) | -$22.34 M(-32.0%) |
| Sep 2022 | - | -$4.25 M(-7.2%) | -$32.86 M(-25.9%) |
| Jun 2022 | - | -$4.59 M(-42.0%) | -$44.34 M(-2.4%) |
| Mar 2022 | - | -$7.91 M(-50.9%) | -$45.45 M(+6.7%) |
| Dec 2021 | -$42.61 M(+279.6%) | -$16.11 M(+2.4%) | -$42.61 M(+31.6%) |
| Sep 2021 | - | -$15.73 M(+176.1%) | -$32.39 M(+67.3%) |
| Jun 2021 | - | -$5.70 M(+12.3%) | -$19.36 M(+29.0%) |
| Mar 2021 | - | -$5.07 M(-13.9%) | -$15.00 M(+33.7%) |
| Dec 2020 | -$11.23 M(-20.1%) | -$5.89 M(+118.5%) | -$11.23 M(+31.0%) |
| Sep 2020 | - | -$2.70 M(+101.0%) | -$8.57 M(-14.6%) |
| Jun 2020 | - | -$1.34 M(+3.6%) | -$10.03 M(-21.1%) |
| Mar 2020 | - | -$1.30 M(-59.9%) | -$12.71 M(-9.6%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2019 | -$14.06 M(+28.7%) | -$3.23 M(-22.2%) | -$14.06 M(-0.8%) |
| Sep 2019 | - | -$4.16 M(+3.3%) | -$14.17 M(+11.7%) |
| Jun 2019 | - | -$4.03 M(+52.4%) | -$12.69 M(+12.1%) |
| Mar 2019 | - | -$2.64 M(-21.1%) | -$11.32 M(+3.6%) |
| Dec 2018 | -$10.92 M(+51.4%) | -$3.35 M(+25.2%) | -$10.92 M(+8.7%) |
| Sep 2018 | - | -$2.67 M(+0.5%) | -$10.05 M(+15.8%) |
| Jun 2018 | - | -$2.66 M(+18.5%) | -$8.68 M(+4.6%) |
| Mar 2018 | - | -$2.24 M(-9.1%) | -$8.29 M(+14.9%) |
| Dec 2017 | -$7.22 M(+58.7%) | -$2.47 M(+89.4%) | -$7.22 M(+6.7%) |
| Sep 2017 | - | -$1.30 M(-42.8%) | -$6.76 M(+1.1%) |
| Jun 2017 | - | -$2.28 M(+95.3%) | -$6.69 M(+31.8%) |
| Mar 2017 | - | -$1.17 M(-42.2%) | -$5.08 M(+11.6%) |
| Dec 2016 | -$4.55 M(+8.4%) | -$2.02 M(+64.2%) | -$4.55 M(+39.8%) |
| Sep 2016 | - | -$1.23 M(+84.3%) | -$3.25 M(-13.9%) |
| Jun 2016 | - | -$666.10 K(+4.5%) | -$3.78 M(-0.4%) |
| Mar 2016 | - | -$637.50 K(-11.7%) | -$3.80 M(-9.5%) |
| Dec 2015 | -$4.19 M | -$721.60 K(-58.9%) | -$4.19 M(+20.8%) |
| Sep 2015 | - | -$1.75 M(+157.2%) | -$3.47 M(+102.0%) |
| Jun 2015 | - | -$682.00 K(-34.2%) | -$1.72 M(+65.8%) |
| Mar 2015 | - | -$1.04 M | -$1.04 M |
FAQ
- What is Entero Therapeutics annual free cash flow?
- What is the all time high annual FCF for Entero Therapeutics?
- What is Entero Therapeutics annual FCF year-on-year change?
- What is Entero Therapeutics quarterly free cash flow?
- What is the all time high quarterly FCF for Entero Therapeutics?
- What is Entero Therapeutics quarterly FCF year-on-year change?
- What is Entero Therapeutics TTM free cash flow?
- What is the all time high TTM FCF for Entero Therapeutics?
- What is Entero Therapeutics TTM FCF year-on-year change?
What is Entero Therapeutics annual free cash flow?
The current annual FCF of ENTO is -$12.88 M
What is the all time high annual FCF for Entero Therapeutics?
Entero Therapeutics all-time high annual free cash flow is -$4.19 M
What is Entero Therapeutics annual FCF year-on-year change?
Over the past year, ENTO annual free cash flow has changed by +$9.47 M (+42.37%)
What is Entero Therapeutics quarterly free cash flow?
The current quarterly FCF of ENTO is -$1.85 M
What is the all time high quarterly FCF for Entero Therapeutics?
Entero Therapeutics all-time high quarterly free cash flow is -$637.50 K
What is Entero Therapeutics quarterly FCF year-on-year change?
Over the past year, ENTO quarterly free cash flow has changed by +$1.59 M (+46.26%)
What is Entero Therapeutics TTM free cash flow?
The current TTM FCF of ENTO is -$12.49 M
What is the all time high TTM FCF for Entero Therapeutics?
Entero Therapeutics all-time high TTM free cash flow is -$1.04 M
What is Entero Therapeutics TTM FCF year-on-year change?
Over the past year, ENTO TTM free cash flow has changed by -$107.90 K (-0.87%)